BioSpace News Archive

Drug Development

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy

EyePoint Pharmaceuticals, Inc. today announced that the first patient has been dosed in the Phase 2 PAVIA clinical trial of EYP-1901.

September 29, 2022
·
6 min read
Business

PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022

PharmaTher Holdings Ltd. today released business highlights and audited financial results for its fiscal year ended May 31, 2022.

September 29, 2022
·
5 min read
Drug Development

OncoNano Medicine Announces Positive Phase 2 Data for Pegsitacianine as an adjunct to Cytoreductive Surgery of Peritoneal Carcinomatosis

OncoNano Medicine, Inc. today announced positive interim clinical results from an ongoing Phase 2 study of its lead clinical development candidate, pegsitacianine.

September 29, 2022
·
4 min read
Drug Development

Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia

Silence Therapeutics plc today announced preliminary results from the single dose component of the GEMINI II phase 1 study of SLN124.

September 29, 2022
·
5 min read
Biotech Bay

CareDx to Host Symposium Covering Innovation in Multimodal Surveillance Including AiCAV for Post-Cardiac Transplant Care

CareDx, Inc. today announced it will host a symposium to describe the latest innovations in post-cardiac transplant care at the HFSA (Heart Failure Society of America) Annual Scientific Meeting 2022 taking place in Washington, D.C., September 30 - October 3.

September 29, 2022
·
5 min read
Pharm Country

Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference

Ocugen, Inc. today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will participate in an in-person fireside chat at the Chardan 6th Annual Genetic Medicines Conference being held October 3-4, 2022 in New York, NY.

September 29, 2022
·
2 min read
Pharm Country

Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting

Axsome Therapeutics, Inc. announced that, following a Type A meeting with the U.S. Food and Drug Administration (FDA), it intends to resubmit its New Drug Application (NDA) for AXS-07 for the acute treatment of migraine in the third quarter of 2023.

September 29, 2022
·
7 min read
Wellbeing Digital to Participate in the Cantor Fitzgerald Symposium on Mental Health Clinics

Wellbeing Digital Sciences Inc. announces that Najla Guthrie, CEO of Wellbeing, will participate in the Cantor Fitzgerald Mental Health Clinics Symposium to be held virtually on October 11, 2022 at 9:00 a.m. ET.

September 29, 2022
·
3 min read
BioMidwest

Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team

Ocuphire Pharma, Inc. announced that it has appointed seven new Key Opinion Leaders across retina, cornea/refractive, and medical optometry to its Medical Advisory Board.

September 29, 2022
·
8 min read
Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer

Genetic Technologies Limited is delighted to announce the recent publication of a paper in the Journal of Precision Medicine authored by GTG science team members, Dr Erika Spaeth, Director of Clinical Affairs, Dr Richard Allman, Chief Scientific Officer, and Dr Gillian Dite, Senior Biostatistician.

September 29, 2022
·
3 min read